Merck Reports Solid 2025 Financials, Advances Pipeline Amidst Keytruda Patent & IRA Headwinds, and Announces Major Restructuring

summarizeSummary

Merck reported increased 2025 sales and EPS, driven by new product approvals and acquisitions, but warned of material future revenue declines for Keytruda due to patent expiration and IRA price setting, alongside a significant drop in Gardasil sales in China.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported total sales of $65.01 billion (up 1% year-over-year, or 2% excluding foreign exchange), GAAP Net Income of $18.25 billion (up 7%), and GAAP EPS of $7.28 (up 8%). Non-GAAP EPS rose 17% to $8.98.

• Keytruda Faces Significant Future Headwinds

  The company expects Keytruda, which represented 49% of total sales in 2025, to be selected for IRA price setting in 2027 (effective Jan 2029), leading to a material negative impact on U.S. sales. Biosimilar competition is also anticipated between 2028 and 2029.

• Major Acquisitions Bolster Pipeline

  Acquired Cidara Therapeutics for approximately $9.2 billion in January 2026, adding MK-1406 (influenza antiviral). Acquired Verona Pharma for $10.4 billion in October 2025, gaining Ohtuvayre (COPD treatment). Two Phase 3 candidates received FDA Commissioner's National Priority Vouchers for expedited review.

• Key Product Approvals and Launches

  Received FDA approval for Keytruda Qlex (subcutaneous Keytruda) in September 2025 and EC approval in November 2025. Launched Capvaxive (pneumococcal vaccine) in EU and Japan, and Enflonsia (RSV antibody) in the U.S. Winrevair (PAH treatment) sales rose to $1.44 billion in 2025.

auto_awesomeAnalysis

Merck's 2025 annual report provides a comprehensive overview of its performance and strategic direction. While the company delivered solid financial results with increased sales and EPS, the filing highlights significant future challenges, particularly the impending patent expiration and Inflation Reduction Act (IRA) price setting for its blockbuster drug, Keytruda, which is expected to materially impact U.S. sales from 2029. The company is actively addressing these challenges through substantial M&A activity to bolster its pipeline, including the acquisition of Cidara Therapeutics for $9.2 billion and Verona Pharma for $10.4 billion, and has initiated major restructuring programs to drive efficiency and cost savings. Investors should monitor the execution of these strategic initiatives and the company's ability to offset future revenue declines from Keytruda and other products facing patent expiry and IRA pricing pressure.